BioSpace News Archive

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced that it has been selected for addition to the NASDAQ Biotechnology Index.

REDUCE-IT® EPA Encore Presentation reinforces Eicosapentaenoic Acid (EPA) levels from VASCEPA® (icosapent ethyl) strongly correlated to cardiovascular outcomes, more so than other biomarkers

The board of directors of Medtronic plc (NYSE: MDT) on Friday, December 11, 2020 , approved the fiscal year 2021 third quarter cash dividend of $0.58 per ordinary share. This quarterly declaration is consistent with the dividend announcement made by the company in June 2020 . Medtronic is a constituent of the S&P 500 Dividend Aris

ActivePure Technologies, LLC, announced that its air purifying technology inactivated over 99.9% of highly concentrated airborne SARS-CoV-2 virus in an enclosed setting in just 3 minutes, below detectable levels.

Efemoral Medical, developer of advanced interventional bioresorbable therapies, today announced the first-in-human (FIH) use of the company’s Efemoral™ Vascular Scaffold System (EVSS) with FlexStep™ Technology in the EFEMORAL I FIH clinical study.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $75.0 million of shares of its common stock

TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases (“TG Therapeutics”), today announced that it has commenced an underwritten public offering of $200,000,000 of its common stock

BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announces that it anticipates data safety monitoring board (DSMB) verbal feedback by the end of December 15, 2020 on interim data from the Company’s pivotal Phase 3 CardiAMP Heart Failure Trial that is currently enrolling nationwide for infusion of BioCardia’s CardiAMP

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that the Company has completed its year-end strategic portfolio product review to optimize the development strategy and priority of each of its programs for 2021 and beyond. “The Company evaluated its current and proposed devel

Astellas Venture Management (President: Kazunori Maruyama , Ph.D, “AVM”), a wholly-owned venture capital subsidiary of Astellas Pharma Inc. and Mission Bay Capital BioLabs (“MBC BioLabs”), a lif